New primary monoclonal antibodies
New primary monoclonal antibodies · 28. April 2026
SYnAbs develops high-quality monoclonal antibodies for Varicella-Zoster Virus (VZV) vaccine quality control. Our RUO antibodies are fully traceable, reproducible, and validated for ELISA, Western blot, and immunofluorescence. Designed for industrial QC, they ensure reliable antigen detection, batch consistency, and long-term supply security for vaccine manufacturers.
New primary monoclonal antibodies · 26. February 2026
Hemoglobin E (HbE) is a highly prevalent structural hemoglobin variant caused by the β-globin Glu26Lys mutation. Despite its major epidemiological relevance, routine detection still relies largely on electrophoresis and HPLC. SynAbs provides monoclonal Research Use Only (RUO) antibodies enabling mutation-specific HbE recognition, variant-level discrimination, and integration into immunoassay and rapid diagnostic platforms.
New primary monoclonal antibodies · 12. January 2026
Hemoglobin A (HbA), the predominant adult hemoglobin isoform, serves as the structural reference for hemoglobin variant discrimination and hemoglobinopathy diagnostics. Accurate HbA recognition is essential for assay calibration, carrier state analysis, and interpretation of mixed hemoglobin profiles. SynAbs provides monoclonal RUO antibodies enabling selective HbA detection, robust structural discrimination versus variant hemoglobins, and integration into immunoassay and rapid diagnostics
New primary monoclonal antibodies · 13. October 2025
Hemoglobin C (HbC) is a clinically relevant structural hemoglobin variant caused by the β-globin Glu6Lys mutation, prevalent in populations of West African descent. Accurate discrimination from HbA and other β-chain variants remains essential in hemoglobinopathy diagnostics. SynAbs provides monoclonal Research Use Only (RUO) antibodies enabling mutation-specific HbC recognition, variant-level discrimination, and integration into immunoassay and rapid diagnostic assay platforms.
New primary monoclonal antibodies · 16. September 2025
Hemoglobin S (HbS), the pathogenic variant underlying sickle cell disease, remains a critical target in hemoglobinopathy diagnostics and screening. SynAbs provides monoclonal Research Use Only (RUO) antibodies enabling mutation-specific HbS recognition, robust variant discrimination versus HbA and related isoforms, and seamless integration into immunoassay and rapid diagnostic platforms. Designed for assay developers and IVD manufacturers working on next-generation hemoglobin variant detection.
New primary monoclonal antibodies · 08. July 2025
SYnAbs innovative mouse and rat RUO monoclonals to detect MRSA strains targeting PBP2a and PBP2b for diagnosis in lateral flow immunoassay
New primary monoclonal antibodies · 13. May 2025
MCR-1-mediated colistin resistance detection using SYnAbs monoclonal antibodies
New primary monoclonal antibodies · 29. April 2025
SYnAbs unique primary monoclonal antibody to specifically detect vancomycin B (vanB) to tackle the threat of antibiotic resistance
New primary monoclonal antibodies · 23. April 2025
SYnAbs RUO monoclonal antibodies of mouse and rat species highly specific to Estradiol without cross-reactivity to close steroid analogs
New primary monoclonal antibodies · 22. April 2025
SYnAbs unique specific monoclonal antibodies for the detection of Vancomycin A without cross-reactivity to Vancomycin B or close analogs for antibiotic resistance diagnosis in lateral flow and other immunoassay formats
SYnAbs S.A.
Rue Auguste Piccard, 48
I-Tech Incubator 2
B-6041 Gosselies
Belgium
BE 0637.716.206
